January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

66

Dr. Dean Ornish - Lifestyle Changes and the Reversal of Alzheimer’s Symptoms (part 1)

Imagine being able to fight the effects of Alzheimer’s through changes to the way you live your daily life. Dr.

LISTEN NOW
65

Music and Mind Series – Part 1 with Renée Fleming: Harnessing the Arts for Health and Wellness

How personal and meaningful are music and the arts to your brain health, mental well-being, and quality of life?

LISTEN NOW
64

Dr. Suzanne LeBlang – Focused Ultrasound Technology and Alzheimer’s Treatment (part 2)

Join us for part 2 of BrainStorm’s interview with Dr.

LISTEN NOW